Clinical Trial Update: Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating post-transplant bortezomib and high-dose cyclophosphamide for graft-versus-host disease prophylaxis; study completed with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancy

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Corewell Health West | Conditions: Hematological Malignancy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-17